What Blech sees in Interferon Sciences

Fallen angels are few and far between, even at currently depressed stock market prices, but New York investor David Blech thinks he has found another one in Interferon Sciences Inc.

Blech, who is investing $10 million for a 26 percent stake in IFSC, told BioCentury, "The technology is really undervalued considering that they have some very strong data on the lack of toxicity of

Read the full 693 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers